In a move aimed at tackling one of the world’s fastest-growing public health threats, Takara Bio and Resistomap Oy have struck a strategic agreement to expand their partnership and fast-track surveillance of antimicrobial resistance (AMR) in the environment.

 

The collaboration combines Takara Bio’s large-scale testing technology with Resistomap’s data-driven AMR intelligence, targeting a major blind spot in global health: the environment. From water systems to agriculture, experts warn that antibiotic resistance is spreading far beyond hospitals—making comprehensive monitoring urgent.

 

"AMR goes beyond the clinic. It moves through water, wastewater, farms, animals, food systems, and the environment. Without environmental surveillance, One Health AMR action is incomplete," said Windi Muziasari, Founder and CEO of Resistomap.

 

The stakes are stark. If left unchecked, AMR could become a leading cause of death by 2050, claiming up to 10 million lives annually. The economic toll is equally severe, with projections of a 3.8% hit to global GDP and losses reaching $5.2 trillion.

 

Governments are already responding. Following the 2024 UN General Assembly High-Level Meeting on AMR, regulations have tightened worldwide—particularly around environmental surveillance. But major hurdles remain, including fragmented workflows, limited testing capacity, and high costs.

 

At the center of the new partnership is the SmartChip Biosecurity Platform, designed to standardize and scale AMR monitoring. By integrating Takara Bio’s SmartChip ND Real-Time PCR System with Resistomap’s cloud-based analytics, the platform delivers rapid, high-volume results—processing thousands of data points in just three hours.

 

"The SmartChip ND System is an automated high-throughput qPCR solution, designed to quantify genes with both precision and efficiency. This technology allows to screen hundreds of targets simultaneously, detecting and quantifying antibiotic resistance genes even at low abundance within complex environmental samples" states Matthieu Lewis, Senior Market Strategy Manager at Takara Bio Europe. 

 

"Unlike standard qPCR systems that allow for up to 384 data points per run, the SmartChip ND system can quantify hundreds of samples and assays in parallel, reaching 5,184 data points per run, 13x faster. This allows for users to multiply the number of environmental samples processed at the same time, while targeting a large number of genes of interest."

 

Once generated, the massive datasets are fed directly into Resistomap’s platform, which converts raw results into actionable insights for researchers, regulators, and public health officials.

 

"To make the most of the data" adds Muziasari, "results are explored using our software, a tool designed for AMR surveillance and reporting. The platform includes four interactive views: the Antibiotic Resistance Gene Index (ARGI), the Gene Reduction view, and Comparative Health Risk view, as well as a dedicated Gene details view for more detailed gene-level exploration".

 

"The reports generated with the Resistomap Platform can be used to examine results over time, across locations, and at the gene level, with flexible visualisation options for both exploration and reporting. Whether monitoring public health, evaluating treatment processes, or supporting environmental protection efforts, the platform transforms complex qPCR data into meaningful insights."

 

The platform also includes predesigned assay kits capable of tracking dozens of resistance-related genes in a single run, streamlining deployment for labs and agencies worldwide. Both companies say further region-specific and targeted kits are already in development.

 

As antibiotic resistance continues its global march, the partnership signals a shift toward faster, more comprehensive environmental surveillance—an effort experts say is critical to staying ahead of a looming public health crisis.